FIELD: pharmaceuticals and veterinary medicine.
SUBSTANCE: invention relates to the field of pharmaceuticals and veterinary medicine and is a method for the course use of a drug based on trazodone succinate for the treatment of separation anxiety in dogs, which consists in administering to an animal in need of such treatment, the specified agent in the first three days of administration - in a single dose of 3-6 mg/kg of body weight, 2 times a day with an interval of 12 hours, on subsequent days - at a single dose of 6-10 mg/kg of body weight, 2 times a day with an interval of 12 hours, where the total duration of the course is determined by the achievement of stable relief of signs of separation anxiety .
EFFECT: effectiveness of the method, safe for animals for long-term use.
1 cl, 7 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COURSE USE OF TRAZODONE SUCCINATE FOR THE TREATMENT OF COGNITIVE DYSFUNCTION IN OLDER DOGS AND CATS | 2022 |
|
RU2792666C1 |
| PHARMACEUTICAL COMPOSITION FOR CORRECTING BEHAVIOR OF CATS AND DOGS IN STRESS SITUATIONS | 2019 |
|
RU2706700C1 |
| NEW APPLICATION OF COMBINED SELECTIVE ANTAGONISTS OF DOPAMINE D2 RECEPTOR AND AGONISTS OF 5-НТ RECEPTOR | 2001 |
|
RU2283648C2 |
| COMPOSITIONS AND METHODS OF TREATING NEUROGENERATIVE DISORDERS | 2019 |
|
RU2828223C2 |
| USING COMPOUND COMBINING PROPERTY OF SEROTONIN REVERSE UPTAKE INHIBITOR AND AGONIST OF 5-HT-RECEPTOR | 2001 |
|
RU2288719C2 |
| PHARMACEUTICAL PREPARATION SHOWING ANTIALCOHOLIC AND NOOTROPIC EFFECTS | 1995 |
|
RU2097034C1 |
| DEXMEDETOMIDINE OR MEDETOMIDINE FOR USE IN THE TREATMENT OF SEPARATION ANXIETY IN DOGS | 2017 |
|
RU2759726C2 |
| 3-β(4-METHOXYBENZYLOXY)PREGN-5-EN-20-ONE FOR USE IN TREATMENT OF DISORDERS RELATED TO CONSUMPTION OF CANNABINOIDS | 2019 |
|
RU2788004C2 |
| METHOD OF TREATING DEPRESSION IN DOGS AND CATS | 2018 |
|
RU2698400C1 |
| METHOD OF POTENTIAL PSYCOTROPIC AGENT CHARACTERISTICS DETECTION | 2006 |
|
RU2328038C1 |
